Online abstract submission opens on 14 April and closes on 17 June 2022.

点此提交摘要>>>Submit Abstract>>>

Submission mode:
Abstract submission is only possible through the online congress profile platform.
Abstracts submitted by post, fax or email will NOT be accepted. The online abstract submission module will NOT be available after 17 June 2022.

IDF congress profile:
In order to submit an abstract, a congress profile must be created. This gives access to the online abstract submission module. The submitting author must ensure accurate contact details are entered. One or more abstracts can be submitted by logging in with this congress profile.

Author Registration:
Presenting authors of accepted abstracts MUST register for the congress by 31 August 2022 and must present their poster(s) onsite in Lisbon, Portugal. If the entire registration fee is not paid by the deadline, the abstract will be automatically withdrawn and will NOT be presented or published.

Presenting author registration: The presenting author must be registered by 31 August 2022. If the presenting author is not registered by this date, their abstract will be REMOVED from the programme.

Presenting authors can still benefit from the early registration rate when registering for the congress by the deadline of 31 August 2022. Author notifications will be sent between 5 and 12 August 2022.

Number of submissions:
There can only be ONE presenting author per abstract. The same abstract CANNOT be submitted multiple times by listing different presenting authors. An author may submit an unlimited number of abstracts.

Originality of abstracts:
Work published in peer-reviewed journals before 5 December 2022 should NOT be submitted to the IDF World Diabetes Congress 2022. Abstracts already presented at face-toface meetings should also not be submitted, unless there are new methods and/or findings. Abstracts already presented at a national virtual meeting can be resubmitted. However, previously submitted work should NOT be resubmitted, if it has been presented at an international virtual meeting.

Instructions：

Topic: There are various categories that have been defined for the abstract programme within the eight streams. Ensure that you select the MOST relevant topic which BEST describes the content of your abstract. Categories are used for reviewing and indexing purposes.

Abstract title:
The title is limited to 120 characters including spaces and should be brief and relevant. Special characters should NOT be used in your title but spelt out instead (e.g. α should be written as alpha, β as beta). Only use standard abbreviations and generic drug names in the title.

Authors:
Up to 12 authors and/or study groups can be listed. Only one institution can be entered per author.

Abstract body

• The abstract structure is laid out under the headings:
  Background, Aim, Method, Results, Conclusion and References
• Font size and style will be automatically configured by the system
• Maximum of 1 Table or 1 Figure will be accepted in the submission field and count towards the character limit. The character deduction for tables is not fixed and will be generated by the character count shown below the submission field. The table/figure should not contain more than 480 characters. The table should have a maximum of 10 columns and 12 rows. Figures should have a maximum of two panels. Images and photographs are NOT allowed.
• Only commonly accepted abbreviations should be used (e.g. GDM, BMI, DM). Treatment groups or drug names should NOT be abbreviated. Less widely recognised abbreviations may be used if introduced on first usage (e.g. ambulatory blood pressure monitoring, ABPM).
• Only approved and generic (non-proprietary) drug names should be used.
• Do NOT enter the title, authors, or grant information into the abstract body, but you can include up to three references at the end of the abstract. All references need to have matching citations in the abstract body text.

Selection:
All submitted abstracts undergo a review process by the Programme Committee. Accepted abstracts are selected for oral poster presentation or e-poster gallery display. The Programme Committee reserves the right to accept or reject any submitted abstract and re-categorise any accepted abstract. The decision of the Programme Committee is final and irrevocable.

Notification:
Notice of acceptance or rejection of submitted abstracts will be sent to the submitting authors from 5 to 12 August 2022. It is the responsibility of the submitting author to inform all other authors of the status of the abstract. A submitting author may also check their congress profile to see the status of the abstract.

 

The IDF World Diabetes Congress 2022 welcomes original abstracts on subjects relevant to the following streams:

• Basic and Translational Science (BTS) 
• Clinical, Therapeutic and Technology Research (CTT)
• Diabetes Complications and Comorbidities (DCC)
• Health Services and Policy (HSP)
• Diabetes in Women (DIW) 
• Education and Integrated Care (EIC)
• Epidemiology and Public Health (EPH)
• Living with Diabetes (LWD)

Download the 摘要提交指南/Abstract Submission Guidelines (pdf).

It gives me great pleasure to invite you to Lisbon, Portugal, for the International Diabetes Federation (IDF) World Diabetes Congress 2022.

We continue to live in extraordinarily difficult times in which people with diabetes are facing the additional health threat posed by Covid-19. We have seen that people living with diabetes can be more susceptible to the worst complications of the virus and share a concern with many colleagues that the current situation may increase diabetes complications over the coming years. We unfortunately anticipate that Covid-19 will continue to impact individuals, health systems and economies for some time. We remain hopeful, however, that the pandemic will be sufficiently under control to enable the global diabetes community to convene safely in  Lisbon.

In the current context, it is important to remember that we are facing an ever-increasing global pandemic of diabetes. 1 in 10 adults across the world – 60 million in the IDF European Region – are living with diabetes. Without significant action to address the global impact of the condition, IDF anticipates that the number will rise to more than 700 million over the next 25 years.

As we continue to mark the centenary of the landmark discovery of insulin, we must keep at top of mind the sad fact that insulin and other fundamental components of diabetes care – monitoring equipment and supplies, oral medicines, education and psychological support – remain beyond the reach of many people with diabetes who need them. It is therefore important that the legacy of Covid-19 should not see resources and attention focused on infectious diseases to the detriment of all non-communicable diseases, including diabetes.

The IDF World Diabetes Congress 2022 in Lisbon provides the ideal forum for the global diabetes community to continue to make the case for the level of attention, recognition and resources that diabetes deserves.  Hosted in the city that is home to the world’s oldest diabetes association, IDF 2022 will provide a unique forum for knowledge exchange, bringing together the extensive global network of physicians, scientists, nurses, educators, other healthcare professionals, government officials, policy makers, media and diabetes associations that IDF represents .

IDF 2022 will harness the latest technologies to ensure a safe and dynamic experience for all delegates and help foster the collaborations, connections and political actions required to keep diabetes at the top of the global health agenda and improve the lives of people living with diabetes and those at risk.

I look forward to welcoming the global diabetes community in Lisbon to shape the future of diabetes through our strong and united global voice.

Professor Andrew Boulton
President, International Diabetes Federation